US Congress House Bill 1220 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on March 15 2013 - 25% progression, died in committee
Action: 2013-03-15 - Referred to the Subcommittee on Energy and Power.
Pending: House Subcommittee on Energy and Power Committee
Text: Latest bill text (Introduced) [PDF]

Asthma Inhalers Relief Act of 2013 - Directs the Administrator of the Environmental Protection Agency (EPA) to: (1) permit the distribution, sale, and consumption in the United States of remaining inventories of CFC epinephrine inhalers manufactured pursuant to the exception for medical devices under the Clean Air Act; (2) not take any enforcement action or otherwise seek to restrict the distribution, sale, or consumption of such inhalers on the basis of any federal law implementing the Montreal Protocol on Substances that Deplete the Ozone Layer; and (3) issue, in response to a request of any distributor or seller of such inhalers, a No Action Assurance Letter stating that the EPA will not initiate an enforcement action relating to the distribution or sale of any such inhaler occurring prior to August 1, 2013. Defines "CFC epinephrine inhaler" to mean any epinephrine inhaler containing chlorofluorocarbons that was manufactured and classified as over-the-counter before January 1, 2012. Terminates this Act on August 1, 2013.

Asthma Inhalers Relief Act of 2013

Rep. Michael Burgess [R-TX]

Rep. John Carter [R-TX]

Rep. John Dingell [D-MI]

Rep. Jim Matheson [D-UT]

Date	Chamber	Action
2013-03-15	House	Referred to the Subcommittee on Energy and Power.
2013-03-15	House	Referred to the House Committee on Energy and Commerce.

Type	Source
Summary	https://www.congress.gov/bill/113th-congress/house-bill/1220/all-info
Text	https://www.congress.gov/113/bills/hr1220/BILLS-113hr1220ih.pdf